{"id":131112,"date":"2026-07-10T13:32:24","date_gmt":"2026-07-10T19:32:24","guid":{"rendered":"https:\/\/trimrx.com\/blog\/?p=131112"},"modified":"2026-07-10T13:32:24","modified_gmt":"2026-07-10T19:32:24","slug":"amycretin-vs-cagrisema-novo-nordisks-two-amylin-bets-compared","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/amycretin-vs-cagrisema-novo-nordisks-two-amylin-bets-compared\/","title":{"rendered":"Amycretin vs CagriSema: Novo Nordisk’s Two Amylin Bets Compared"},"content":{"rendered":"

Novo Nordisk is pursuing two different ways to combine amylin with GLP-1 for weight loss, and amycretin and CagriSema represent that split strategy: one packs both actions into a single molecule, the other combines two separate drugs. Both are investigational. CagriSema is further along and has larger confirmed weight-loss data, while amycretin offers the convenience potential of a pill and a high ceiling. Here’s how Novo’s two amylin approaches compare.<\/p>\n

Same Idea, Different Design<\/h3>\n

Both drugs harness the same insight: amylin and GLP-1 are separate appetite-regulating hormones, and hitting both produces more weight loss than either alone. But they execute it differently. CagriSema is a combination of two drugs (cagrilintide, an amylin analog, plus semaglutide, a GLP-1 drug) delivered together as a weekly injection. Amycretin is a single molecule engineered to activate both the amylin and GLP-1 receptors on its own, and it’s being developed in both injectable and oral pill forms. So it’s a combination approach versus an all-in-one molecule.<\/p>\n

Head to Head<\/h3>\n
\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nAmycretin<\/th>\nCagriSema<\/th>\n<\/tr>\n<\/thead>\n
Design<\/td>\nSingle molecule (GLP-1 + amylin)<\/td>\nTwo-drug combination<\/td>\n<\/tr>\n
Forms<\/td>\nInjection and pill<\/td>\nInjection only<\/td>\n<\/tr>\n
Approximate weight loss<\/td>\nInjection around 22%; pill around 13%<\/td>\nAbout 22.7%<\/td>\n<\/tr>\n
Development stage<\/td>\nEntering phase 3<\/td>\nPhase 3 complete (FDA filed)<\/td>\n<\/tr>\n
Developer<\/td>\nNovo Nordisk<\/td>\nNovo Nordisk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Weight Loss: Both Strong, CagriSema Confirmed<\/h3>\n

On weight loss, both reach impressive levels. CagriSema produced about 22.7% in its completed phase 3 REDEFINE 1 trial. Amycretin’s injectable form reached the low 20% range in earlier testing, published in The Lancet<\/a> in 2025, though from smaller, earlier-stage studies. So CagriSema has the more robust, confirmed weight-loss data, while amycretin’s numbers are promising but from earlier trials. Amycretin’s oral form produces less (around 13% in short studies), which is expected for a pill.<\/p>\n

The Key Difference: Amycretin Could Be a Pill<\/h3>\n

Amycretin’s standout advantage is format flexibility. Because it’s a single molecule, it can be formulated as an oral pill, something CagriSema (a two-drug injectable combination) can’t easily do. For patients who prefer pills or dislike injections, an oral amylin-GLP-1 drug would be appealing. Consider a hypothetical patient weighing the two: if they want the strongest confirmed injectable, CagriSema leads; if they’d prefer a pill and are willing to wait, amycretin’s oral form is the draw. CagriSema is also closer to market, having already been filed for FDA approval.<\/p>\n

Status and Availability<\/h3>\n

Neither is available. CagriSema is further along (Novo Nordisk filed for FDA approval in late 2025), while amycretin is entering phase 3 for both its formats. Both are Novo Nordisk drugs, so the company is essentially hedging across two amylin strategies, which is a sign of how promising the amylin approach is overall.<\/p>\n

What This Means for You Right Now<\/h3>\n

Neither amycretin nor CagriSema is available, and TrimRx does not offer them. TrimRx provides currently available options, including compounded semaglutide and compounded tirzepatide plus brand GLP-1 injectables. If you want strong weight loss now, those available options are the practical choice while Novo’s amylin drugs work through development.<\/p>\n

Frequently Asked Questions<\/h3>\n

What’s the difference between amycretin and CagriSema?<\/h4>\n

Both combine amylin and GLP-1 action, but amycretin is a single molecule doing both (available as an injection or pill), while CagriSema is two separate drugs combined into one injection. CagriSema has more confirmed late-stage data; amycretin offers pill potential.<\/p>\n

Which produces more weight loss?<\/h4>\n

CagriSema has the stronger confirmed result (about 22.7% in completed phase 3). Amycretin’s injectable reached the low 20% range in earlier trials, and its pill form produces less (around 13%). CagriSema’s data is more robust for now.<\/p>\n

Are either available?<\/h4>\n

No. Both are investigational Novo Nordisk drugs available only through clinical trials. CagriSema has been filed for FDA approval; amycretin is entering phase 3. TrimRx offers approved alternatives.<\/p>\n

To focus on treatments available today, you can explore the options available to you now<\/a> with a licensed provider.<\/p>\n

This information is for educational purposes and is not medical advice. Amycretin and CagriSema are investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk is pursuing two different ways to combine amylin with GLP-1 for weight loss, and amycretin and CagriSema represent that split strategy: one…<\/p>\n","protected":false},"author":7,"featured_media":130071,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[],"class_list":["post-131112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=131112"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131112\/revisions"}],"predecessor-version":[{"id":131113,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/131112\/revisions\/131113"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/130071"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=131112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=131112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=131112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}